XOMA(XOMA) - 2019 Q4 - Annual Report

Financial Strategy and Revenue Generation - XOMA Corporation has a portfolio of economic rights to future milestone and royalty payments from partnered pre-commercial therapeutic candidates, with a focus on expanding its pipeline through acquisitions[1][15] - The company has entered into multiple Royalty Purchase Agreements, including a $15.0 million agreement with Agenus, which allows XOMA to receive up to $59.5 million in potential future milestones and unlimited royalties[19] - XOMA's acquisition of rights from Aronora includes a $6.0 million upfront payment and potential tiered milestone payments of up to $85.0 million per product based on cumulative royalties exceeding $250.0 million[22] - The company has a collaboration with Novartis that includes a $37.0 million upfront fee and eligibility for up to $480.0 million in development, regulatory, and commercial milestones for the anti-TGFβ antibody program[31] - The company aims to diversify its revenue streams by acquiring pre-commercial stage drug candidates with high revenue potential and long market exclusivity[15] - The company is eligible for low single-digit to mid-teens royalty rates on sales of licensed products from its collaborations with Novartis and Takeda[28][31] - The company is engaged in a royalty aggregator strategy, seeking to acquire future royalties and milestone payments related to drug development and sales[69] - The company’s future revenue is expected to be primarily based on milestone and royalty payments from its partnered programs[200] Financial Condition and Capital Structure - The company reported net losses of $2.0 million and $13.3 million for the years ended December 31, 2019, and December 31, 2018, respectively, with an accumulated deficit of $1.2 billion as of December 31, 2019[78] - The company has financed its operations primarily through the sale of equity securities, debt, and royalty interests, and payments received under collaboration and licensing arrangements[79] - The company may need to raise additional funds to acquire milestone and royalty interests, and there is uncertainty regarding the availability of funds at acceptable costs[80] - The company may need to raise significant additional capital in the future, which could lead to substantial dilution for existing stockholders[95] - The company may sell additional equity or convertible debt securities to fund operations, which could impose restrictions on business and result in dilution[99] - The company has experienced ownership changes that limit the future use of net operating loss carry-forwards and certain tax attributes[109] - The Tax Cuts and Jobs Act of 2017 reduced the corporate tax rate from 35% to 21%, but the overall impact on the company's financial condition remains uncertain[112] Partnerships and Collaborations - The company has established partnerships with major pharmaceutical firms, which are critical for the success of its royalty aggregator business model[1][15] - The company has a Royalty Purchase Agreement with Bioasis Technologies, involving an upfront payment of $0.3 million and potential future payments of up to $0.2 million based on development milestones[207] - The company is entitled to low single-digit royalties on future sales of Bayer Products and 10% of all future developmental, regulatory, and sales milestones related to these products[206] - The company has the right to receive low-single digit percentage of net sales from non-Bayer Products and 10% of all future payments related to these products[206] Risks and Challenges - The company faces competition from other entities seeking to aggregate royalties or provide alternative financing to development-stage biotechnology and pharmaceutical companies[56] - The company relies on third parties for the achievement of regulatory and developmental milestones, which directly impacts potential royalty and milestone payments[73] - The company has a risk of credit exposure due to potential defaults or bankruptcies of licensors or licensees associated with acquired royalty streams[70] - The company’s financial condition may be adversely affected if drug products in clinical development are not successfully commercialized[71] - The company’s ability to receive royalty payments is dependent on the accuracy of its licensees' sales and accounting functions[72] - The company’s business model is subject to various risks, including competition, regulatory changes, and reliance on third-party developments[67] - The company faces potential penalties for violations of healthcare laws, which could adversely affect its business operations[186] - The company is subject to risks related to third-party service providers, which could affect product candidate development and manufacturing programs[85] Intellectual Property and Regulatory Environment - The company holds a number of patents and applications in the United States and internationally, but the patent position is highly uncertain[58] - The company relies on patent protection to safeguard its technologies, but the effectiveness of such protection can be uncertain and subject to legal challenges[142] - If intellectual property rights are not adequately protected, competitors may commercialize similar technologies, harming the company's market position[145] - The company may face claims of patent infringement, which could prevent the development or commercialization of products if licenses are not obtainable[151] - Regulatory approvals are required for the company's licensees' product candidates to be manufactured and marketed, which could impact commercialization[118] - The initiation of clinical trials requires approval from health authorities, and the process can take several years and is extremely expensive[119] - The FDA and foreign health authorities have substantial discretion in the drug approval process, and failure can occur at any stage, potentially delaying or preventing product approval[123] Operational and Management Considerations - The company has significantly restructured its business to focus on becoming a royalty aggregator, which may affect its financial performance and balance sheet if not executed successfully[82] - The company relies heavily on licensee relationships, and any disputes or breaches could reduce financial resources, including milestone payments and future royalty revenues[84] - The company has experienced significant volatility in its stock price, ranging from a high of $28.85 to a low of $11.50 from January 1, 2019, to March 5, 2020[93] - The company had 10 employees as of March 5, 2020, and faces challenges in attracting and retaining qualified personnel due to competition and high living costs in California[153] - The loss of key personnel, such as the CEO or CFO, could delay or prevent the achievement of business objectives[152] - Cyberattacks and data breaches pose significant risks to the company's sensitive information and could lead to substantial remediation costs and operational disruptions[159] - Shareholder lawsuits could result in substantial damages and divert management's focus from business activities, impacting financial performance[167]